{"id":36637,"date":"2024-11-25T10:05:16","date_gmt":"2024-11-25T09:05:16","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=36637"},"modified":"2024-11-21T12:53:09","modified_gmt":"2024-11-21T11:53:09","slug":"wirksamkeit-von-zweimal-jaehrlich-depemokimab-s-c-bei-patienten-mit-schwerem-eosinophilem-asthma","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/wirksamkeit-von-zweimal-jaehrlich-depemokimab-s-c-bei-patienten-mit-schwerem-eosinophilem-asthma","title":{"rendered":"Wirksamkeit von zweimal j\u00e4hrlich Depemokimab s.c. bei Patienten mit schwerem eosinophilem Asthma"},"content":{"rendered":"<p>\u00dcber anti-eosinophile Therapieans\u00e4tze bei eosinophiler \u00d6sophagitis und COPD mit Eosinophilie haben wir berichtet ,\u00a0. Die Dom\u00e4ne dieser Strategie ist aber das eosinophile Asthma bronchiale, f\u00fcr das bereits derartige Wirkstoffe zugelassen sind . Eine inad\u00e4quate Kontrolle des eosinophilen Asthmas f\u00fchrt h\u00e4ufiger zu Exazerbationen und erh\u00f6htem Bedarf an systemischen Glukokortikosteroiden ,\u00a0. Beides hat langfristig schwerwiegende Folgen f\u00fcr [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00dcber anti-eosinophile Therapieans\u00e4tze bei eosinophiler \u00d6sophagitis und COPD mit Eosinophilie haben wir berichtet ,\u00a0. Die Dom\u00e4ne dieser Strategie ist aber das eosinophile Asthma bronchiale, f\u00fcr das bereits derartige Wirkstoffe zugelassen sind . Eine inad\u00e4quate Kontrolle des eosinophilen Asthmas f\u00fchrt h\u00e4ufiger zu Exazerbationen und erh\u00f6htem Bedarf an systemischen Glukokortikosteroiden ,\u00a0. Beides hat langfristig schwerwiegende Folgen f\u00fcr [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[470,467,6100,6101,6102],"class_list":["post-36637","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-asthma","tag-asthma-bronchiale","tag-depemokimab","tag-swift-1-studie","tag-swift-2-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/36637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=36637"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/36637\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=36637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=36637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=36637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}